Interview: Marc Vandelaer – CEO, IBBL (Integrated BioBank of Luxembourg)
CEO Marc Vandelaer reveals why the Luxembourg biobank IBBL is more than a traditional biobank and how, despite the short time since its inception in 2010, it has begun to…
IBBL (Integrated BioBank of Luxembourg) is an autonomous not-for-profit institute dedicated to supporting biomedical research for the benefit of patients. IBBL is an integrated research infrastructure offering bioservices, including the collection, processing, analysis and storage of biological samples and associated data. In addition, IBBL carries out research to optimise biospecimen processing and certify biospecimen quality. IBBL is ISO 9001:2008 and NF S96-900:2011 certified, as well as ISO 17025:2005 accredited*. IBBL’s mission is to provide biospecimen related services and a biobanking infrastructure for applied medical research. IBBL’s vision is to be an international centre of excellence in biobanking and a valued partner in developing better healthcare solutions. IBBL is an autonomous institute, organised within the Luxembourg Institute of Health (LIH).
Contact
IBBL (Integrated BioBank of Luxembourg)
For Next Generation Healthcare
6, rue Nicolas Ernest Barblé, L-1210, Luxembourg
Corporate Website: www.ibbl.lu
Public Website: www.biobank.lu
Tel: +352 26 970 – 520
Email: communications@ibbl.lu
CEO Marc Vandelaer reveals why the Luxembourg biobank IBBL is more than a traditional biobank and how, despite the short time since its inception in 2010, it has begun to…
Novartis is one of Belgian pharma’s biggest investors across manufacturing and R&D, contributing EUR 598.9 million to GDP in 2022, creating 4,403 direct and indirect jobs, and reaching 5,349,628 million…
After a 25-year-long career at Roche, spent at local affiliates in Switzerland, Germany, and the Netherlands, as well as in global positions in Switzerland and the US, Marie-José Borst took…
Carl Laurent, managing director and CEO of Siemens Healthineers BeLux, sits down with PharmaBoardroom to explain Siemens Healthineers’ footprint and impact in Belgium and Luxembourg, the importance of appreciating diagnostics…
Sabena Solomon, general manager of GSK Benelux, speaks about her first impressions of the Belgium market, having come from GSK Finland, and her initial priorities for leading the affiliate. Solomon…
Christos Andriopoulos, managing director of Merck, speaks about his experience transitioning from global operations to leading a country subsidiary. Andriopoulos goes on to explain the company’s unique positioning as an…
Javier Aracil, country manager of Allergan in Belgium and Luxembourg, introduces the priorities and objectives as he set as he entered his first country manager position coming from holding key…
Isabelle De Walsche, managing director of Gedeon Richter in Belgium, the Netherlands, and Luxembourg gives an update on the affiliate’s development since its establishment in 2012. De Waslche goes on…
Brecht Vanneste, associate VP and managing director of MSD in Belgium and Luxembourg, highlights the strategic significance of the affiliate as an important location for early-stage clinical trials and home…
Frank Swaelens, general manager of IQVIA in Belgium and Luxembourg, offers insights into the healthcare and life science ecosystem of Belgium and highlights the opportunities that exist for the country…
Despite its miniscule size, Luxembourg has managed to specialize in three key areas and now has a strong claim to be a global leader in personalized healthcare, e-health and data…
Sound infrastructure, a prime location in the heart of Europe, government support, and an unwavering focus on quality are all helping make the tiny principality of Luxembourg a serious player in…
Novartis’ newest Head for the Grand-Duchy of Luxembourg provides a fascinating insight into the Luxembourg market and reveals how this small nation has found itself in pole position for future…
See our Cookie Privacy Policy Here
